European Neuropsychopharmacology

Metabotropic receptors: ten years of research
pp. 159-159(1)
Author: Bockaert J.

Personality disorders are disorders of the personality?
pp. 159-160(2)
Author: Loacute pez-Ibor J.J.

The dopamine and glutamate hypotheses of schizophrenia -- therapeutic implications of an integrated view
pp. 160-160(1)
Author: Carlsson A.

Peripheral markers in obsessive-compulsive disorder: effect of treatments
pp. 161-161(1)
Authors: Marazziti D.; Pfanner C.; Rossi A.; Gemignani A.; Milanfranchi A.; Ravagli S.; Lensi P.; Presta S.; Cassano G.B.

The relevance of behavioral probes in obsessive-compulsive disorder
pp. 161-162(2)
Authors: Dolberg O.T.; Sasson Y.; Cohen R.; Zohar J.

Treating obsessive-compulsive disorder with serotonin reuptake inhibitors
pp. 162-163(2)
Author: Koran L.M.

The use of antiandrogen therapy in refractory obsessive-compulsive male patients
pp. 163-163(1)
Authors: Casas M.; Barcia D.; Vallejo J.; Turoacute n V.; Salorio P.; Ruiz E.; Duro P.; Tejero A.

Treatment of severe OCD
pp. 163-164(2)
Authors: Goodman W.K.; Byerly M.; Murphy T.

Imaging of neuroleptic occupancy in schizophrenia
pp. 164-164(1)
Authors: Kerwin R.; Pilowsky L.; Busatto G.; Costa D.; Ell P.

Movement disorders in schizophrenia: current considerations
pp. 164-165(2)
Author: Casey D.E.

Health economic considerations in the treatment of schizophrenia
pp. 165-165(1)
Author: Souetre E.

Update on new atypical antipsychotics
pp. 165-165(1)
Author: Tollefson G.D.

Reintegration strategies in schizophrenia: maximizing outcomes
pp. 165-166(2)
Author: Littrell K.H.

Alpha-2 adrenergic dysfunction in depression: standardization and validation of the clonidine REM suppression test (CREST)
pp. 166-166(1)
Author: Schittecatte M.

Affective disorder treatments and second messengers in the brain
pp. 167-167(1)
Authors: Moslashrk A.; Jensen J.B.; Petersen B.; Thrane J.; Geisler A.

The comparative effects of SSRIs and TCAs on sleep architecture
pp. 167-168(2)
Author: Nutt D.J.

The stress-induced anhedonia model of depression predicts antidepressant-like properties of the COMT inhibitor tolcapone
pp. 168-168(1)
Authors: Moreau J.-L.; Jenck F.; Martin J.R.; Mutel V.; Da Prada M.

Long-term SSRI treatment increases Ca²⁺/calmodulin phosphorylation of presynaptic proteins: a new site in the mechanism of action of antidepressants
pp. 168-169(2)
Authors: Popoli M.; Vocaturo C.; Buffa L.; Pereza J.; Racagni G.

Molecular pharmacology of NMDA receptors
pp. 169-169(1)
Author: Williams K.

Therapeutic potential of drugs acting on excitatory amino acid receptors
pp. 169-170(2)
Authors: Scatton B.; Avenet P.; Benavides J.; Besnard F.; Carter C.; Duverger D.; Graham D.; Leacute onardon J.; Santa-Maria R.; Langer S.Z.

Glutamate antagonists in animal models of cerebral ischaemia
pp. 170-170(1)
Author: McCulloch J.

The pharmacology of CERETAT^TM (CNS1102) and early clinical results
pp. 171-171(1)
Author: Gamzu E.

Clinical treatment of ischaemic stroke: present and future
pp. 171-172(2)
Authors: Fieschi C.; Cavalletti C.; Montinaro E.

Depression and the risk of mortality
pp. 172-172(1)
Author: Glassman A.H.

Treatment response to serotonin reuptake inhibitors in minor depressions
pp. 172-173(2)
Author: Rosenbaum J.F.

SSRIs in the treatment of melancholic patients
pp. 173-173(1)
Authors: Roose S.P.; Glassman A.H.; Attia E.

The optimal therapeutical area for SSRIs: panic disorder
pp. 173-174(2)
Author: Wade A.G.

Obsessive compulsive disorder (OCD) and social phobia
pp. 174-174(1)
Author: Ballenger J.C.

Differences between the SSRI
pp. 174-174(1)
Author: Broslashsen K.

WHO international study of somatoform disorders -- a review of methods and results
pp. 175-175(1)
Author: Janca A.

Somatoform disorders and personality in the general population and in psychiatric outpatients
pp. 175-175(1)
Author: Cloninger C.R.

The present nosography of somatoform disorders: results of the Italian epidemiological study of somatoform disorders
pp. 175-176(2)
Authors: Tacchini G.; Musazzi A.; Recchia M.; Altamura A.C.; Carta M.G.

The co-occurrence of panic and somatization disorder: analysis from a genetic-epidemiological vantage point
pp. 176-176(1)
Authors: Battaglia M.; Politi E.; Bertella S.; Bellodi L.

Psychopharmacological treatments of somatoform disorders
pp. 176-177(2)
Author: Altamura A.C.

Focus on biological basis of somatoform disorders
pp. 177-177(1)
Authors: Del Zompo M.; Ruiu S.; Severino G.; Cherchi A.; Bocchetta A.; Usaia P.

New perspectives on physiopathology and therapy of somatoform diseases
pp. 177-177(1)
Authors: Fratta W.; Mancinelli R.; Diana M.; Azzena G.B.; Forgione A.

Impulse control and serotonergic drugs: commonalities and differences in animal models
pp. 177-178(2)
Authors: De Vry J.; Schreiber R.; de Beun R.

Clinical, nonhuman primate and rodent studies on impulse control
pp. 178-178(1)
Authors: Linnoila M.; Higley J.D.; Hall F.S.; Weight F.; Nielsen D.; Goldman D.; Virkkunen M.

Therapeutic attempts in impulse control disorders
pp. 178-179(2)
Authors: Loacute pez-Ibor J.J.; Ruiacute z J.S..

Platelet markers in aggression
pp. 179-180(2)
Authors: Oerlinghausen B.M..; Uebelhack R.

Psychiatric effects of the anabolic steroids: aggression and impulse dyscontrol
pp. 180-180(1)
Authors: Katz D.L.; Pope H.G.

Multiple ATP receptors in the nervous system: new and widely-distributed drug targets
pp. 180-180(1)
Author: Barnard E.A.

Regulation of gene expression in adult brain
pp. 180-181(2)
Authors: Vanderhaeghen J.J.; Schiffmann S.N.; Mailleux P.; Zhang F.; Van Breacute e L.

Regulatory mechanisms of neurotrophic factor gene expression in the central nervous system
pp. 181-181(1)
Authors: Riva M.A.; Molteni R.; Lovati E.; Fumagalli F.; Racagni G.

Functional and pharmacological distinctions between subtypes of dopamine D-2 receptors
pp. 181-182(2)
Authors: Spano P.F.; Memo M.; Missale C.; Pizzi M.; Sigala S.; Valerio A.

Differential induction of early gene expression in the CNS by antipsychotics
pp. 182-183(2)
Author: Roque P.

Provocation of panic as a tool for investigating the disorder
pp. 183-183(1)
Author: Bourin M.

Panic disorder and the serotonin system
pp. 183-184(2)
Authors: Westenberg H.G.M.; den Boer J.A.

SSRIs in panic disorder
pp. 184-184(1)
Author: Lecrubier Y.

The relationship between panic and agoraphobia
pp. 184-185(2)
Author: Klein D.F.

Carbon dioxide hypersensitivity and panic spectrum disorders
pp. 185-185(1)
Authors: Perna G.; Bellodi L.

Has the response of positive symptoms to antipsychotics changed?
pp. 185-186(2)
Author: Kane J.M.

Are primary negative symptoms treatable?
pp. 186-187(2)
Authors: Barnes T.R.E.; Phillips M.A.

Quality of life as an outcome variable in the treatment of schizophrenic patients
pp. 187-187(1)
Authors: Meise U.; Kemmler G.; Holzner B.

Movement disorders -- do [ldquo ]atypical[rdquo ] antipsychotics make a difference?
pp. 187-188(2)
Author: Gerlach J.

Advantages of atypical antipsychotics in the maintenance treatment of schizophrenia
pp. 188-188(1)
Author: Kissling W.

Pharmacodynamic and pharmacokinetic profile of an [ldquo ]ideal[rdquo ] neuroleptic: is there any?
pp. 188-188(1)
Author: Altamura A.C.

Broadening treatment perspectives of schizophrenia: a clinical update on seroquel
pp. 189-189(1)
Author: Fleischhacker W.W.

When do antidepressants work?
pp. 189-189(1)
Author: Derivan A.T.

Early improvement predicts response
pp. 189-190(2)
Author: Bech P.

Protein phosphorylation system as a biochemical marker to study onset of antidepressant action
pp. 190-190(1)
Authors: Perez J.; Mori S.; Caivano M.; Garbini S.; Dorigo A.; Popoli M.; Brunello N.; Smeraldi E.; Racagni G.

Can two week studies be used to establish efficacy?
pp. 190-191(2)
Author: Montgomery S.A.

Enhanced antidepressant responses with antagonists of somatodendritic 5-HT_1A receptors. Basic and clinical studies
pp. 191-191(1)
Authors: Artigas F.; Romero L.; Bel N.; Peacute rez V.; Alvarez E.

Therapeutic strategies for rapid onset and improved efficacy: present and future
pp. 191-192(2)
Author: de Montigny C.

Animal models in alcohol research
pp. 192-192(1)
Authors: Colombo G.; Agabio R.; Balaklievskaia N.; Lobina C.; Reali R.; Fadda F.; Gessa G.L.

Is there a role for neurosteroids in alcoholism?
pp. 192-193(2)
Authors: Romeo E.; Pompili E.; di Michele F.; Furnari C.; Fucci P.; Pasini A.

Carbohydrate deficient transferrin (CDT) in comparison to other biological markers in alcoholism
pp. 193-194(2)
Authors: Ackenheil M.; Sanktjohannser A.; Soyka M.; Jenner A.; Karlsson M.

Pharmacotherapeutic approaches in relapse prevention
pp. 194-194(1)
Author: Chick J.D.

Basic and clinical research leading to the use of naltrexone in the treatment of alcoholism
pp. 194-195(2)
Authors: O'Brien C.P.; Volpicelli J.R.

Experience with naltrexone and psychotherapy in treating alcoholism in Europe
pp. 195-195(1)
Author: Soyka M.

Dopamine D1 receptor activation decreases GABA release through adenosine A1 receptor after chronic cocaine treatment
pp. 196-196(1)
Authors: Williams J.T.; Bonci A.

Somatodendritic dopamine stimulates glutamate and GABA release via D₁ receptors
pp. 196-196(1)
Authors: Kalivas P.W.; X.-Y. L.

Functional role of somatodendritic dopamine release in basal ganglia circuitry
pp. 196-196(1)
Authors: Abercrombie E.D.; Timmerman W.; DeBoer P.

Involvement of the nigral D₁ receptor in neuroleptic-induced oral dyskinesias in rats: clinical implications
pp. 196-197(2)
Author: Tamminga C.A.

Subthreshold syndromes of depression
pp. 197-197(1)
Authors: Preisig M.; Angst J.; Merikangas K.R.

Do antidepressants work in mild depression?
pp. 197-198(2)
Author: Montgomery S.A.

Acute and long-term pharmacotherapeutic strategies in pure dysthymia: efficacy of sertraline and imipramine
pp. 198-198(1)
Author: Kocsis J.

Cross-over studies of chronic resistant depression
pp. 198-199(2)
Authors: Keller M.; Zucker M.E.

Pharmacotherapy of depression subtypes
pp. 199-199(1)
Author: Kasper S.

Managing the first episode of schizophrenia: the role of new therapies
pp. 200-200(1)
Author: McCreadie R.G.

Cognitive dysfunction in schizophrenia: comparison of treatment with a novel atypical antipsychotic agent versus conventional neuroleptic drugs
pp. 200-201(2)
Author: Gallhofer B.

Treatment resistant schizophrenia: new insights into neurobiology and treatment
pp. 201-201(1)
Authors: Weinberger D.R.; Lipska B.K.

Treatment-resistant schizophrenia: clinical experience with new antipsychotics
pp. 202-202(1)
Authors: Dufour H.; Bondolfi G.; Baumann P.; Seywert F.

Proper psychosocial rehabilitation for the stabilised schizophrenic patients: the role of new therapies
pp. 202-203(2)
Author: Peuskens J.

The impact of managed care systems on relapse prevention and quality of life for patients with schizophrenia
pp. 203-203(1)
Author: Glazer W.M.

Underlying neurotransmitter changes in Alzheimer's disease
pp. 203-204(2)
Authors: Francis P.T.; Alder J.T.; C. P.L.-H.C.; Chessell I.P.; Clarke N.A.; Dijk S.N.; Procter A.W.; Webster M.-T.; Bowen D.M.

Alzheimer's disease: neurochemistry of Alzheimer's disease and its clinical implications
pp. 204-204(1)
Author: Amaducci L.

Treatment strategies in Alzheimer's disease
pp. 204-205(2)
Author: Levy R.

Xanomeline: the first study of the safety and efficacy of an M1 agonist in mild and moderate Alzheimer's disease
pp. 205-205(1)
Authors: Bodick N.C.; Offen W.

Disease altering therapeutic strategies based on the molecular dissection of the amyloid lesions in Alzheimer's disease
pp. 205-206(2)
Authors: Beyreuther K.; Masters C.L.

Defective protein kinase C [alpha ] and [beta ]-amyloid precursor protein secretion in fibroblasts from sporadic Alzheimer's disease patients
pp. 206-206(1)
Authors: Govoni S.; Bergamaschi S.; Trabucchi M.; Battaini F.; Binetti G.; Bianchetti A.; Racchi M.

Pharmacological treatment of anxiety disorders: an overview
pp. 206-207(2)
Authors: Leacute pine J.P.; Pelissolo A.

MAOIs in social phobia
pp. 207-207(1)
Authors: Katschnig H.; Berger P.

Benzodiazepines in panic disorders: focus on clonazepam
pp. 207-208(2)
Author: Rosenbaum J.F.

Are there more effective drug treatments for obsessive compulsive disorder?
pp. 208-208(1)
Authors: Fineberg N.A.; Roberts A.; Montgomery S.A.

5HT2C receptor agonists and antagonists in animal models of anxiety
pp. 209-209(1)
Authors: Martin J.R.; Bouml s M.; Jenck F.; Kouml hler C.; Moreau J.-L.; Sleight A.J.; Stadler H.; Wichmann J.

The role of serotonin in dysthymia and other affective spectrum diseases
pp. 209-210(2)
Author: Kasper S.

Role of serotonin in psychosis
pp. 210-210(1)
Authors: Farde L.; Nyberg S.; Halldin C.

OCD: the promise and limitation of serotonin selective agents
pp. 210-210(1)
Author: Ravizza L.

Premenstrual mood disorders: clinical experience with serotonergic-based therapies
pp. 210-211(2)
Author: Steiner M.

New alternatives for the pharmacotherapy of anxiety disorders
pp. 211-212(2)
Authors: den Boer J.A.; van Megen H.J.G.M.; Westenberg H.G.M.

The role of serotonin in emerging therapeutic opportunities: the beginning not the end
pp. 212-213(2)
Author: Tollefson G.D.

Novel neuroleptics acting on presynaptic dopaminergic receptors
pp. 213-213(1)
Authors: Scatton B.; Perrault G.; Gonon F.; Depoortere R.; Sanger D.; Schoemaker H.

Pharmacology of anhedonia
pp. 214-214(1)
Author: Willner P.

Dopaminergic influence on motivational processes: improving positive and/or negative symptom
pp. 214-215(2)
Authors: Boyer P.; Lecrubier Y.

Acute and long-term treatment of schizophrenia: different strategies for positive and negative symptoms?
pp. 216-216(1)
Author: Rein W.

Assessment of negative symptoms in the long-term treatment of psychosis
pp. 216-217(2)
Author: Kane J.M.

Endogenous cannabinoid ligands -- chemical and biological studies
pp. 217-217(1)
Authors: Mechoulam R.; Shabat S.B.; Hanuscaron L.; Fride E.; Barg Y.; Vogel Z.; Bayewitch M.

GABAergic drugs and addictive behavior
pp. 217-218(2)
Authors: Tempesta E.; Janiri L.; Mannelli P.

Opioid receptor blockade
pp. 218-218(1)
Author: Kosten T.R.

Is dopamine involved in opiate addiction?
pp. 218-219(2)
Authors: van Ree J.M.; Gerrits M.A.F.M.

Opiate agonists and antagonists in the treatment of heroin addiction: differential outcomes according to methadone and naltrexone treatment practice
pp. 219-219(1)
Authors: Mannaioni P.F.; Botti P.; Caramelli L.; Gambassi F.; Occupati B.; Peruzzi S.; Pistelli A.; Smorlesi C.; Zorn A.M.; Masini E.

The impact of depression on survival following myocardial infarction
pp. 219-220(2)
Authors: Lespeacute rance F.; Smith N.F.; Talajic M.

Vital exhaustion, cardiac events, and the relationship to depression
pp. 220-221(2)
Author: Kop W.J.

Anger, hostility and progression of arteriosclerotic disease
pp. 221-221(1)
Authors: Kaplan G.A.; Salonen J.T.; Julkunen J.; Kauhanen J.; Salonen R.

Mechanisms linking death and depression
pp. 221-222(2)
Authors: Glassman A.H.; Bigger J.T.; Roose S.P.

Can antidepressants be used safely in patients with serious heart disease?
pp. 222-222(1)
Authors: Roose S.P.; Glassman A.H.; Woodring S.

Plasticity of astrocytes in aging
pp. 222-223(2)
Authors: Vernadakis A.; Kentroti S.; Kazazoglou T.; Lambropoulos E.F.; Geladopoulos T.; Stefanis C.

Growth factors as products and regulators of astrocytes: CNTF, FGF, TGF-[beta ]1-3, and GDNF
pp. 223-223(1)
Authors: Unsicker K.; Meyer V.; Flanders K.C.; Wirth S.B.; Rufer M.; Krieglstein K.; Suter-Crazzolara C.

Oxysterol (7[beta ]-hydroxycholesteryl-3-oleate) promotes serotonergic reinnervation in the lesioned rat spinal cord by reducing glial reaction
pp. 223-223(1)
Authors: Privat A.; Gimenez y Ribotta M.; Mersel M.

Neuron-glia interactions in glutamate and GABA homeostasis: implications for epilepsy and neurodegenerative diseases
pp. 224-224(1)
Author: Schousboe A.

Enhanced extracellular glutamate and delayed neurotoxicity in cortical neuroglial cocultures exposed to the glutamate uptake inhibitor PDC
pp. 224-224(1)
Authors: Volterra A.; Bezzi P.; Rizzini B.L.; Trotti D.; Rossi D.; Racagni G.

Prevalence, lifecourse and disability in social phobia
pp. 224-225(2)
Author: Judd L.L.

WPA educational programme on social phobia
pp. 225-225(1)
Author: e Silva J.A.C.

Basic and clinical aspects of social phobia
pp. 225-226(2)
Authors: den Boer J.A.; van Vliet I.M.; Westenberg H.G.M.

Reversible inhibitors of monamine oxidase A (RIMA) in the treatment of social phobia
pp. 226-226(1)
Author: Siegel J.L.

Interaction of drugs and psychotherapy in social phobia
pp. 227-227(1)
Authors: Katschnig H.; Sachs G.

Subclinical and atypical forms of bipolarity
pp. 227-227(1)
Author: Cassano G.B.

Distinction of recurrent brief depression from other fluctuating brief depressions. Consequences for therapy evaluation
pp. 227-228(2)
Authors: Benkert O.; Fickinger M.P.; Philipp M.; Heun R.

Is rapid cycling a valid subtype of bipolar disorder?
pp. 228-228(1)
Authors: Maj M.; Magliano L.; Pirozzi R.; Marasco C.; Guarneri M.

New treatments for bipolar disorder
pp. 228-229(2)
Author: Tohen M.

Evidence of the efficacy of maintenance-electroconvulsive therapy (M-ECT) in rapid cycling bipolar disorders
pp. 229-229(1)
Authors: Vanelle J.M.; de Carvalho W.; Olieacute J.P.; Locirc o H.

Functional organization of the ventral striatum: focus on limbic-striatal loops
pp. 229-229(1)
Author: Everitt B.J.

Physiological function of the ventral striatum
pp. 229-230(2)
Authors: Le Moal M.; Piazza P.V.; Maccari S.; Casolini P.; Rougeacute -Pont F.; Simon H.

Abnormal mesolimbic dopamine function following neonatal hippocampal damage: implications for schizophrenia
pp. 230-230(1)
Authors: Lipska B.K.; Lillrank S.M.; Wood G.K.; Weinberger D.R.

Dopaminergic hypofunction in the nucleus accumbens as a substrate for depression
pp. 230-231(2)
Author: Willner P.

Prefronto-cortical versus ventral striatal selectivity in the action of motivationally active drugs and stimuli
pp. 231-232(2)
Author: Di Chiara G.

Free radical scavengers in neuroprotection
pp. 232-232(1)
Authors: Riederer P.; Gsell W.; Frouml lich L.; Gouml tz M.

Physiopathological role of glutamate receptors in mesencephalic neurons in vitro
pp. 232-233(2)
Authors: Ambrosini A.; Bresciani L.; Orlandi V.; Fracchia S.; Racagni G.; Brunello N.

Evoked potentials monitoring in Parkinson's disease therapy
pp. 233-234(2)
Authors: Stanzione P.; Pierantozzi M.; Semprini R.; Traversa R.; Bernardi G.

Electrophysiological monitoring of dopaminergic therapy using short-latency median nerve somatosensory evoked potentials (SEPS) in Parkinson's disease
pp. 234-234(1)
Author: Mauguiegrave re F.

The effect of treatment on motor cortical activity in Parkinson's disease
pp. 234-235(2)
Author: Rothwell J.C.

Age-dependent behaviors and developmental psychopharmacology in the context of behavioral teratology
pp. 235-235(1)
Author: Spear L.P.

Psychoactive drugs and early social interactions in rodents
pp. 235-236(2)
Authors: Laviola G.; Terranova M.L.

The role of behavior in the assessment of developmental neurotoxicity in humans and animals
pp. 236-236(1)
Author: Elsner J.

Neurobehavioral changes produced by developmental exposure to environmental pollutants
pp. 236-237(2)
Authors: De Salvia M.A.; Carratugrave M.R.; Cagiano R.; Cortese I.; Renna G.; Siro-Brigiani G.; Cuomo V.

Ontogeny of firing patterns of dopamine neurons in rat midbrain slices. Role of NMDA receptor activation
pp. 237-238(2)
Authors: Mereu G.; Casula A.; Lilliu V.; Vicini S.; Francesconi W.; Gessa G.L.

Animal models of developmental neurotoxicity and their relevance to human exposures: the example of lead
pp. 238-238(1)
Authors: Winneke G.; Lilienthal H.; Bonatz A.

Anatomical abnormalities in the temporal lobe in schizophrenia
pp. 238-239(2)
Authors: Shenton M.E.; McCarley R.W.; Kikinis R.; Hokama H.H.; Nestor P.G.; O'Donnell B.F.; Dickey C.C.; Wible C.G.; Jolesz F.A.

Magnetic resonance imaging of the frontal lobe in schizophrenia
pp. 239-239(1)
Authors: Pol H.E.H.; Baareacute W.F.C.; Gispen-de Wied C.C.; Mali W.P.T.M.; Kahn R.S.

Receptor binding studies in schizophrenia
pp. 239-240(2)
Author: Sedvall G.

Neuroanatomical abnormalities and symptomatology of schizophrenia
pp. 240-240(1)
Authors: Vita A.; Dieci M.; Giobbio G.M.; Caputo A.; Ghiringhelli L.; Tenconi F.; Comazzi M.; Invernizzi G.

Basal ganglia shrinkage in schizophrenia: magnetic resonance and neuropsychological study
pp. 240-241(2)
Authors: Rossi A.; Stratta P.; Mancini F.; Mattei P.; Daneluzzo E.; Casacchia M.

Functional neuroimaging to evaluate atypical antipsychotic compounds: an FDG PET study of SDZ MAR 327
pp. 241-242(2)
Authors: Potkin S.G.; Wu J.; Fallon F.; Bera R.; Carreon D.; Telford J.; Plon L.; Keator D.; Anand R.; Hartman R.

Life events and the aetiology of depression
pp. 242-242(1)
Author: Brown G.W.

Mechanisms of chronic mild stress-induced anhedonia
pp. 242-242(1)
Author: Papp M.

Stress peptides and HPA axis reactivity in depression
pp. 242-243(2)
Authors: Nemeroff C.B.; Stout S.C.; Owens M.J.

Implication of central and peripheral glutamate receptors in experimental stress ulcers
pp. 243-244(2)
Authors: Baraldi M.; Truzzi C.; Veneri C.; Chiessi C.; Cannazza G.; Zanoli P.

Tumorigenesis and immune function in a transgenic mouse model of the endocrine changes seen in depression characterized by defective glucocorticoid feedback inhibition and HPA axis hyperactivity
pp. 244-244(1)
Authors: Blom J.M.C.; Barden N.; Racagni G.

Influence of stress and glucocorticoids on psychostimulant abuse
pp. 244-245(2)
Authors: Piazza P.V.; Deroche V.; Rouge-Pont F.; Haney M.; Maccari S.; Le Moal M.

ECT in Parkinson's disease, with and without depression
pp. 245-245(1)
Author: Trimble M.R.

Psychopathology and prevalence of depression in Parkinson's disease
pp. 245-245(1)
Author: Ring H.A.

Interactions between dopaminergic, serotoninergic and nitric oxide-containing systems in the CNS. Their possible involvement in Parkinson's disease and depression
pp. 245-246(2)
Author: Steinbusch H.W.M.

Treatment of depression in Parkinson's disease: a meta-analysis
pp. 246-246(1)
Authors: Verhey F.R.J.; Havermans A.G.M.; Klaassen T.; van Praag H.M.

Parkinson's disease and depression: one disease?
pp. 246-246(1)
Authors: Martignoni E.; Verri A.P.; Nappi G.

The biological basis and pharmacological treatment of anxiety: do the elderly differ?
pp. 247-247(1)
Author: Leonard B.E.

Clinical aspects of anxiety states in the elderly
pp. 247-248(2)
Authors: Casacchia M.; Roncone R.

The clinical decision in long-term treatment of anxiety disorders with benzodiazepines
pp. 248-248(1)
Authors: Pancheri P.; Biondi M.

The treatment of anxiety disorders in the elderly
pp. 248-249(2)
Authors: Sheehan D.V.; Ray B.A.; Sheehan K.H.

Chronicity and continuity in depressive state
pp. 249-249(1)
Authors: Cassano G.B.; Cecconi D.

Pharmacological and clinical experience in nefazodone treatment of depression
pp. 249-250(2)
Author: Preakorn S.H.

Modern approach in the treatment of anxiety associated with depression
pp. 250-250(1)
Author: Keller M.B.

The effects of nefazodone on sleep profiles in depression
pp. 250-250(1)
Author: Armitage R.

Sexual dysfunction and other tolerability in the management of depression
pp. 250-251(2)
Author: Baldwin D.

Sleep and neuroendocrine profiles in depression and mania
pp. 251-251(1)
Authors: Linkowski P.; Mendlewicz J.

Preclinical/clinical aspects of interactions between serotonin and norepinephrine
pp. 251-251(1)
Author: Blier P.

Pharmacotherapeutic profile of venlafaxine
pp. 251-252(2)
Author: Preskorn S.H.

Rapid onset of action: clinical relevance to antidepressant action
pp. 252-253(2)
Author: Montgomery S.A.

Efficacy and safety of venlafaxine in major depression
pp. 253-254(2)
Author: Lecrubier Y.

An overview of CNS drug discovery at Eli Lilly and Company
pp. 254-254(1)
Author: Paul S.M.

The discovery and pharmacology of xanomeline, a muscarinic M1 receptor agonist for Alzheimer's disease
pp. 254-254(1)
Authors: Shannon H.E.; Bymaster F.P.; Calligaro D.O.; DeLapp N.W.; Mitch C.H.; Ward J.S.; Olesen P.; Sheardown M.J.; Swedberg M.D.B.; Sauerberg P.

Xanomeline in mild and moderate Alzheimer's disease; the effects of a novel M1 agonist on behavior
pp. 254-255(2)
Authors: Bodick N.C.; Offen W.

Olanzapine: an exciting atypical antipsychotic -- the preclinical profile
pp. 255-256(2)
Authors: Moore N.A.; Bymaster F.P.; Calligaro D.O.; Fuller R.W.; Rasmussen K.; Stockton M.E.; D. T.W.; Tye N.C.

Olanzapine: an exciting atypical antipsychotic -- the clinical experience
pp. 256-256(1)
Authors: Tollefson G.D.; Beasley C.M.; Tran P.V.; Sanger T.

A randomized, naturalistic cost-effectiveness study in a managed health care setting
pp. 256-257(2)
Authors: Heiligenstein J.H.; Simon G.

Biological enrichment in the study of drug: placebo differences of patients with affective disorders
pp. 257-257(1)
Authors: James S.; Heiligenstein J.; Faries D.; Tollefson G.

Adaptive randomization in clinical trials: a placebo compromise
pp. 257-258(2)
Authors: Wood A.; Faries D.; Heiligenstein J.

A double-blind, placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder
pp. 258-258(1)
Author: Blashko C.A.

Premenstrual dysphoric disorder: is it simply PMS?
pp. 259-259(1)
Author: Endicott J.

The role of continuation treatment in chronic depression
pp. 259-260(2)
Authors: Keller M.; Zucker M.E.

Advances in the pharmacotherapy of obsessive-compulsive disorder
pp. 260-260(1)
Author: Bisserbe J.C.

The role of SSRIs in anxiety disorders
pp. 260-261(2)
Author: Nutt D.

Epidemiology and public health significance of depressive disorders
pp. 261-262(2)
Author: Judd L.L.

Neurobiology of antidepressant treatments
pp. 262-262(1)
Author: de Montigny C.

The new antidepressant Org 3770 (mirtazapine) modulates noradrenergic and serotonergic transmission by blocking [alpha ]₂-adrenergic autoreceptors
pp. 262-262(1)
Authors: de Boer T.; Nefkens F.; van Helvoirt A.

Clinical efficacy of mirtazapine: a review
pp. 262-263(2)
Author: Kasper S.

Safety of mirtazapine: a review
pp. 263-264(2)
Author: Montgomery S.A.

Lithium-potassium cotransport across the erythrocyte membrane in affective disorders
pp. 265-265(1)
Authors: Hiyama T.; Yoshimuta N.; Nakayama K.; Ushijima s.

Guanine nucleotide binding proteins (G proteins) in drug-free depressed patients
pp. 265-265(1)
Authors: Karege F.; Bovier P.; Schwald M.; Stepanian R.; Hilleret H.; Gaillard J.M.

Assessment of changes in regional cerebral blood flow in patients with seasonal affective disorder (SAD) using single photon emission tomography
pp. 265-266(2)
Authors: Rieder N.; Neumeister A.; Podreka I.; Kasper S.

The effects of CCK-4 on plasma arginine-vasopressin and oxytocin levels in women with and without premenstrual dysphoric disorder
pp. 266-266(1)
Authors: Le Melleacute do J.M.; Bradwejn J.; Koszycki D.; Bellavance F.; Steinberg S.; Halbreich U.; Legrand J.-M.; Bichet D.G.

Enhanced sensitivity to CCK-4 in women with severe premenstrual symptoms (PDD)
pp. 266-266(1)
Authors: Le Melleacute do J.M.; Bradwejn J.; Koszycki D.; Bellavance F.; Bichet D.G.; Halbreich U.; Steinberg S.; Legrand J.-M.

The prevalence of psychotropic drug use in the population presenting to general practitioner in the urban area of Padua
pp. 266-266(1)
Authors: Borgherini G.; Semenzin M.; Gardellin F.; Pavan L.; Giorgetti R.; Ferrara S.D.

Clinical predictors of response to antidepressants in geriatric depressions
pp. 266-267(2)
Authors: Koncevoy V.A.; Andrusenko M.P.; Sheshenin V.S.

Thyrotropin response to thyrotropin-releasing hormone in depression: thyroidological aspects
pp. 267-267(1)
Author: Bunevicius R.

ACTH, prolactin, cortisol after dexamethasone in mental illnesses with postmenopausal onsets
pp. 267-267(1)
Author: Molnaacute r G.

Clinical efficacy of left and right unilateral electroconvulsive seizures in affective disorders and schizophrenia
pp. 267-268(2)
Authors: Nikolaenko N.N.; Egorov A.Y.

Evolution of platelet and plasma serotonin levels following electroconvulsive therapy in patients with major depressive episode
pp. 268-268(1)
Authors: Quintin P.; Spreux-Varoquaux O.; Kollenbach K.; Gregoire A.; Advenier C.; Chevalier J.F.

Space perception changes as a result of cognitive dysfunction in affective disorders and schizophrenia
pp. 268-268(1)
Authors: Egoroy A.Y.; Nikolaenko N.N.; Freiman E.A.; Dobrovoslkaya N.V.

Eye fixations and recognition memory in depression
pp. 268-269(2)
Authors: Fleury E.; Buquet C.; Thomas P.; Goudemand M.; Hache J.C.; Charlier J.R.

Prevalence of psychiatric comorbidity in patients with diabetes mellitus type I with and without poor metabolic control
pp. 269-269(1)
Authors: Eiber R.; Balssa N.; Grimaldi A.; Lecrubier Y.; Bisserbe J.C.

Short-term availability of brain serotonin is crucial for antidepressant effect of light therapy
pp. 269-269(1)
Authors: Neumeister A.; Rieder N.; Hesselmann B.; Kasper S.

Light therapy is able to prevent the relapse after partial sleep deprivation
pp. 269-269(1)
Authors: Neumeister A.; Rieder N.; Gouml ssler R.; Lucht M.; Kapitany T.; Kasper S.

Cerebral blood flow pattern of treatment responsiveness in major depression
pp. 270-270(1)
Authors: Thomas P.; Vaiva G.; Maron M.; Baux P.; Notardonato L.; Rescle C.; Dutoit D.; Goudemand M.; Steinling M.

Cortical and subcortical brain changes in bipolar affective disorders: a magnetic resonance imaging study
pp. 270-270(1)
Authors: Puzdot ynacute ski S.; Berecedil sewicz M.; Koszewska I.; Poniatowska R.; Kryst-Widzacute gowska T.

Plasma prolactin level in major depression and antidepressant therapy
pp. 270-270(1)
Authors: Landowski J.; Sowinnacute ski P.; Wichowicz H.

The depression unknown to the general practitioner
pp. 270-271(2)
Authors: Zdanowicz N.; Reynaert C.; Janne P.; Boriani M.; Vause M.

Case report: mood disorder with maniac features in a patient treated with GM-C.S.F.
pp. 271-271(1)
Authors: Zdanowicz N.; Chatelain C.; Wulleman P.; Reynaert C.; Janne P.; Vause M.

Three months activity report of 104 Italian pychiatric centres
pp. 271-271(1)
Authors: Pancheri P.; Marconi P.L.

Study of anticipation in bipolar affective disorder
pp. 271-272(2)
Authors: Heiden A.M.; Miller-Reiter E.; Willinger U.; Meszaros K.; Scharfetter J.; Lenzinger E.; Resinger E.; Aschauer H.N.; Kasper S.

Suicidal behavior in depression: role of serotonin and noradrenaline
pp. 272-272(1)
Authors: Pitchot W.; Ansseau M.; Hansenne M.; Moreno A.G.

Depression and suicide on gotland, before and after the depression-training program for general practitioners
pp. 272-272(1)
Authors: Rihmer Z.; Pihlgren H.; Rutz W.

Endothelium released factors in depression
pp. 272-273(2)
Authors: D'Amato C.C.; Bianchi A.; Pitari G.M.; Candido P.; Rapisarda V.

Depression and direct central serotonin (B-HT)
pp. 273-273(1)
Authors: Becker U.; Laakmann G.; Baghai T.; Pfeiffer B.; Kauert G.

Treatment resistant depression -- a biochemical hypothesis
pp. 273-273(1)
Authors: Norman T.; Gupta R.K.; Burrows G.D.

Red blood cell L-tryptophan uptake in depression: a putative indicator of the antidepressant drug choice?
pp. 273-273(1)
Authors: Jeanningros R.; Serres F.; Azorin J.M.; Dassa D.; Noel F.

Are Wistar-Kyoto rats a genetic animal model of depression?: similarities with humans in the temporal response to imipramine
pp. 274-274(1)
Author: Lahmame A.

Additive effects of glyburide and antidepressants in the forced swimming test: further evidence for involvement of the potassium channels
pp. 274-274(1)
Authors: Guo W.Y.; Todd K.; Bourin M.; Hascoeuml t M.

Influence of some psychotropic drugs on the anti-immobility effects of serotonin reuptake inhibitors in the forced swimming test in mice
pp. 274-275(2)
Authors: Thieacute bot M.-H.; Da-Rocha M.A.; Puech A.J.

The additive effects of quinine on antidepressants in the forced swimming test in mice
pp. 275-275(1)
Authors: Guo W.Y.; Todd K.; Bourin M.

Measure of neuroreceptors and behaviour in a putative chronobiological model of affective disorders
pp. 275-275(1)
Authors: Schelstraete I.; Jeanjean A.P.; Weyers M.H.; Maloteaux J.M.

Effects of co-administration of anxiolytic-drugs on reversal by serotonin uptake inhibitors of deficit behavior in learned helplessness paradigm
pp. 275-276(2)
Authors: Martin P.; Lacroix P.; Billardon M.; Guillou N.; Puech A.

The antidepressant effects of 5-HT1A agonist buspirone in the learned-helplessness paradigm: a post-synaptic mediation
pp. 276-276(1)
Author: Martin P.

Antidepressant effects of milnacipran in the learned helplessness test in rats
pp. 276-276(1)
Authors: Lacroix P.; Rocher N.; Gandon J.M.; Panconi E.

Effect of sigma ligands on NMDA receptor function in the bulbectomy model of depression: a behavioural study in the rat
pp. 276-277(2)
Authors: Debonnel G.; Dryver E.; Lavoie N.

An investigation of the acute effects of sertraline in a rat social interaction test
pp. 277-277(1)
Authors: Lightowler S.; Kennett G.A.; Tulloch I.F.; Blackburn T.P.

A rapid antidepressant response may be induced by selectively activating postsynaptic serotonin_1a receptors
pp. 277-278(2)
Authors: Bergeron R.; de Montigny C.; Blier P.

Pindolol potentiates the effect of paroxetine on 5-HT efflux in the rat dorsal raphe nucleus
pp. 278-278(1)
Authors: Davidson C.; Stamford J.A.

Acute and chronic effects of imipramine on serotonergic function. Microdialysis studies in conscious rats
pp. 278-278(1)
Authors: Artigas F.; Bel N.

Effects of selective antidepressants on the sensitivity of the central alpha-2-adrenergic receptors
pp. 279-279(1)
Authors: Babinski T.; Totcacute S.; Marinkovicacute D.; Stanisavljevicacute D.; Paunovicacute V.R.

Protein kinase c activity and distribution in brain after chronic treatment with antidepressants
pp. 279-279(1)
Authors: Hrdina P.D.; Mann C.D.; Vu T.B.

Changes in the subcellular distribution of cAMP receptors after chronic treatment with fluvoxamine and paroxetine
pp. 279-280(2)
Authors: Mori S.; Caivano M.; Garbini S.; Dorigo A.; Zanardi R.; Perez J.; Racagni G.

Chronic antidepressant administration inhibits microtubule assembly in rat cerebral cortex
pp. 280-280(1)
Authors: Miyamoto S.; Asakura M.; Sasuga Y.; Imafuku J.; Gamo Y.; Osada K.

Effects of lithium on rat brain energy metabolism
pp. 280-280(1)
Authors: Imafuku J.; Pettegrew J.W.

Neuropeptides in central nervous system. Effects of lithium and electroconvulsive treatment
pp. 281-281(1)
Authors: Wahlund B.; Jimeneacute z P.; Haij K.; Danieli B.; Gruber S.; Matheacute A.A.; Stenfors C.; Theodorsson E.

Effect of lithium on inositol trisphophate formation in rat brain as determined by in vivo microdialysis
pp. 281-281(1)
Authors: Gur E.; Newman M.E.; Lerer B.

Pharmacological differences between selective serotonin reuptake inhibitors: interaction with 5-HT₂ and sigma binding sites in human brain in vitro
pp. 281-281(1)
Authors: Lowther S.; De Paermentier F.; Horton R.W.; Tulloch I.F.; Crompton M.R.

Motor effects of some selective serotonin reuptake inhibitors following direct injection into the red nucleus of the rat: evidence for involvement of sigma receptors
pp. 281-282(2)
Authors: Leonard B.E.; Faherty C.; Earley B.

The influence of different amitriptyline doses on its concentrations and pharmacokinetics
pp. 282-282(1)
Authors: Pokrajac M.; Miljkovicacute B.; Timotijevicacute I.

Contribution of lysosomal trapping to the tissue uptake of desipramine; its significance for pharmacokinetics and the pharmacokinetic interaction
pp. 282-283(2)
Authors: Daniel W.; Bickel M.H.; Honegger U.E.

Interactions between mianserin and opioid receptor subtype selectivity
pp. 283-283(1)
Authors: Pick C.G.; Backer M.M.; Schreiber S.

Involvement of serotoninergic system in the analgesic effect of tricyclic antidepressants
pp. 283-283(1)
Authors: Ghelardini C.; Galeotti N.; Bartolini A.

The Citalopram Challenge Test (CCT) as a probe for serotonergic function in depression
pp. 283-284(2)
Authors: Kapitany T.; Schindler S.D.; Barnas C.; Neumeister A.; Sieghart W.; Kasper S.

Effects of paroxetine and bupropion on event-related potentials and spectral frequency
pp. 284-284(1)
Authors: Camp-Bruno J.A.; Lifshitz K.; Lee K.; Linn G.S.; O'Keeffe R.T.

Fluoxetine, a selective 5-hydroxtryptamine uptake inhibitor, increases the locomotor hyperactivity induced by MK-801, a non-competitive NMDA receptor antagonist
pp. 284-284(1)
Authors: Maj J.; Rogoacute z Z.; Skuza G.

An autoradiographic comparison of ³H-paroxetine and ³H-imipramine in human whole brain sections
pp. 284-285(2)
Authors: Miller J.; Bowery N.; Tulloch I.

Cerebral metabolic effects of fluvoxamine: an it in vivo [¹⁴C]2-deoxy-D-glucose study in rats
pp. 285-285(1)
Authors: Freo U.; Pizzolato G.; Merico A.; Ruggero S.; Dam M.; Battistin L.; Pietrini P.; Dani A.

Action of reboxetine on selective drug metabolizing enzymes in rat liver
pp. 285-285(1)
Authors: Fiorentini F.; Castelli M.G.; Dostert P.; Benedetti M.S.; Oesch F.; Arand M.

The dopamine system is involved in antidepressant sleep deprivation - a possible mechanismon of antidepressant action?
pp. 285-286(2)
Authors: Ebert D.; Albert R.; May A.; Kaschka W.P.; Barocka A.

Pharmacotherapy of depression in combination therapy with anxiolytics in non-comorbid depressive patients
pp. 286-286(1)
Author: Molnaacute r G.

Efficacy of fluoxetine in comparison to maprotiline and amitriptyline in major depression with anxious features
pp. 286-286(1)
Authors: Bugarski-Kirola D.; Totic S.; Damjanovic A.; Zivkovic D.

Tryptophan and Serotonin in Panic Disorder and Depression: Effect of Clomipramine Treatment
pp. 286-287(2)
Authors: Fekkes D.; Timmerman L.; Pepplinkhuizen L.

Double-blind comparison of three fixed doses of sertraline and placebo in patients with panic disorder
pp. 287-287(1)
Authors: DuBoff E.; England D.; Ferguson J.M.; Londborg P.D.; Rosenthal M.H.; Smith W.; Wiese C.; Wolkow R.M.

Psychopharmacological treatment of anorexia nervosa
pp. 287-287(1)
Authors: Cebollada A.; Chinchilla A.; Vega M.; Padiacute n J.J.; Montes J.M.; Guzmaacute n G.; Diacute az M.

Fluoxetine treatment of bulimia nervosa
pp. 287-288(2)
Authors: Vega M.; Chinchilla A.; Cebollada A.; Padiacute n J.J.; Guzmaacute n G.; Diacute az M.

The treatment of eating disorders with tianeptin
pp. 288-288(1)
Author: Atchkova M.

Fluvoxamine induced change of 5 HT receptor sensitivity in impulsive borderline personality disorder
pp. 288-288(1)
Authors: Rinne T.; Gans E.; Vernimmen R.; den Boer J.A.; Westenberg H.G.M.; van Tilburg W.

Practical aspects of long-term treatment
pp. 288-289(2)
Author: Malt U.F.

Stability as a factor of tricyclic antidepressants response in dysthymia
pp. 289-289(1)
Authors: Veltischev D.Y.; Gurevich J.M.; Seravina O.F.

The factor of antidepressant treatment response in dysthymia
pp. 289-289(1)
Authors: Veltischev D.Y.; Gurevich J.M.; Seravina O.F.

The treatment of dysthymia with sertraline: a double-blind placebo-controlled trial in dysthymic outpatients without major depression
pp. 289-290(2)
Authors: Guelfi J.D.; Wiseman R.L.

The treatment of dysthymic patients: fluvoxamine versus amitriptyline
pp. 290-290(1)
Authors: Amore M.; Ricci M.; Zazzeri N.

Therapeutical approach to dysthymia
pp. 290-290(1)
Authors: Fernaacute ndez G.; Ocio S.

Assessment of the evolution of anxiety during a treatment of major depressive disorders in ambulatory patients in general practice with fluoxetine (Prozac) 20 mg
pp. 290-291(2)
Authors: Mesters P.; Martens S.; Taymans J.

Onset of action of fluoxetine 20 mg (Prozac) among ambulatory patients suffering from depressive disorders
pp. 291-291(1)
Authors: Mesters P.; Sangeleer M.; Bussios G.; Bourgeois M.

Up-regulation of 5-HT_2C receptors by citalopram and fluoxetine in rat brain
pp. 291-291(1)
Authors: Syvauml lahti E.K.G.; Laakso A.; Pauml lvimauml ki E.-P.; Kuoppamauml ki M.; Hietala J.

The effects of fluoxetine in patients receiving nutritional counselling for bulimia nervosa
pp. 291-292(2)
Authors: Russell J.; Beumont P.; Touyz S.; Buckley C.; Lowinger K.; Talbot P.; Dowton L.; Hasky R.; Allars H.; Johnson G.

Clinical differences in response to mianserin and fluoxetine in depressive patients
pp. 292-292(1)
Authors: Lavergne F.; Berlin I.; Payan C.; Besanccedil on G.

Combined treatment with serotonin reuptake selective inhibitors in depression (I). Evaluation of therapeutic efficacy
pp. 292-292(1)
Authors: Valverde J.I.F.; Loza A.A.S.; Montes M.J.R..; Martiacute nez M.L.D.; Caballero J.L.V..

Combined treatment with serotonin reuptake selective inhibitors in depression (II). Aspects concerning tolerance and toxicity in clinical practice
pp. 292-293(2)
Authors: Loza A.A.S.; Valverde J.I.F.; Montes M.J.R..; Martiacute nez M.L.D.; Caballero J.L.V..; Docio E.Q.

Antidepressants and neuroleptic malignant syndrome
pp. 293-293(1)
Authors: Assion H.J.; Heinemann F.; Laux G.

Dosulepine -- an adiuvant treatment of oncological pain
pp. 293-293(1)
Authors: Tondlavaacute H.; Jakoubkovaacute J.; Bascaron tecky J.

Idiopathic blepharospasm treated successfully with fluoxetine: do SSRI's have some dopaminergic effect?
pp. 293-294(2)
Authors: Schreiber S.; Pick C.G.

Sleep quality and day-time alertness in responders and non-responders to fluoxetine
pp. 294-294(1)
Authors: Dossenbach M.; Meszaros K.; Meyer J.W.

Possible association of suicidal behavior with selective serotonin reuptake inhibitors. The effect of citalopram on five depressed patients
pp. 294-294(1)
Authors: Trikkas G.; Markianos M.; Trikka D.

Acute and subchronic effects of mirtazapine (1530 mg nocte) and mianserin (3060 mg nocte) on psychomotor and actual driving performance and sleep in healthy, young volunteers
pp. 294-295(2)
Authors: Ramaekers J.G.; Muntjewerff N.D.; O'Hanlon J.F.

Compliance with different classes of antidepressant drugs
pp. 295-295(1)
Authors: Koutouvidis N.; Zacharakis C.

Efficacy of antidepressant medications for treatment of mild and moderate depression
pp. 295-295(1)
Authors: Fonzo V.; Scotta M.; Rocca P.; Zanalda E.; Ravizza L.

Changes in acute phase proteins in depressed patients, during treatment with fluoxetine and venlafaxine
pp. 295-296(2)
Authors: Sluzewska A.; Houml rning-Rohan M.; Sobieska M.; Rybakowski J.K.; Amsterdam J.D.

Serotonin-related symptoms and adrenergic status in depressed patients treated with clomipramine
pp. 296-296(1)
Authors: Lejoyeux M.; Rouillon F.; Adeacute s J.

Pharmacotherapy in depression during switch from depression to mania in patients with bipolar affective disorder (BD)
pp. 296-296(1)
Author: Koszewska I.

Multiple and single dose pharmacokinetics of milnacipran in major depressive patients
pp. 296-297(2)
Authors: Retz W.; Becker T.; Schmidtke A.; Riederer P.; Beckmann H.

Moclobemide in the treatment of depressive syndrome in schizophrenia
pp. 297-297(1)
Authors: Jasovic-Gasic M.; Nikolic-Balkoski G.; Totic S.; Acimovic B.; Kuzmanovic V.

The possibilities of automid (moclobemide) administration in the treatment of affective disorders
pp. 297-297(1)
Authors: Timotijevicacute I.; Kovaccaron evicacute S.; Tomovicacute A.; Kosticacute D.

Treatment of severe recurrent major depression: comparative efficacy and tolerability of moclobemide and impiramine
pp. 298-298(1)
Authors: Hochstrasser B.; Ferrero F.; Gachoud J.-P.; Gasser U.E.; Mascetti R.; Meyer J.W.; Wacker H.R.

Efficacy of moclobemide-therapy in depressed patients -- above 65 years old
pp. 298-298(1)
Author: Radics J.

Dimensional assessment of onset of action of antidepressants -- a comparative study of moclobemide versus clomipramine in depressed patients with blunted affect and psychomotor retardation
pp. 298-299(2)
Authors: Jouvent R.; Payan C.; Mikkelsen H.; Fermanian J.; Millet V.; Dufour H.

Comparison of the effects of nefazodone and fluoxetine on sleep architecture and sleep efficiency in depressed patients
pp. 299-299(1)
Authors: Armitage R.; Yonkers K.; Rush A.J.; Cole D.; Novak K.

Delusional depression: SSRIs vs tricyclics responsiveness
pp. 299-299(1)
Authors: Conte G.; Calzeroni A.; Ferrari R.; Guarneri L.; Sacchetti E.

SSRIs: a homogeneous class of antidepressants with non homogeneous responsiveness in major depression
pp. 299-300(2)
Authors: Conte G.; Calzeroni A.; Guarneri L.; Pergami A.; Sacchetti E.

Dopamine receptor binding in major depression: changes before and after treatment with selective serotonin reuptake inhibitors
pp. 300-300(1)
Authors: Klimke A.; Larisch R.; Janz A.; Vosberg H.; Muuml ller-Gauml rtner H.W.; Gaebel W.

Effect of lorazepam on the pharmacokinetics of reboxetine in healthy volunteers
pp. 300-300(1)
Authors: Fiorentini F.; Poggesi I.; Jannuzzo M.G.; Dostert P.; Strolin Benedetti M.; Seiberling M.

Pharmacokinetics of reboxetine in healthy volunteers of different ages
pp. 300-300(1)
Authors: Jannuzzo M.G.; Pellizzoni C.; Poggesi I.; Rocchetti M.; Frigerio E.; Dostert P.; Ryde M.; Karlmark B.; Rouml nn O.; Strolin Benedetti M.

Effect of reboxetine on the pharmacokinetics of lorazepam in healthy volunteers
pp. 300-301(2)
Authors: Jannuzzo M.G.; Dostert P.; Strolin Benedetti M.; Bosc M.; Renoux A.

Endocrine response to lithium challenge in unmedicated rapid-cycling patients
pp. 301-301(1)
Authors: Whybrow P.; Redei E.; Gyulai L.

Lithium treatment and suicide prevention in affective disorders
pp. 301-301(1)
Author: Ahrens B.

Open comparative study of lithium carbonate, carbamazepine and sodium valproate prophylactic use in affective and schizoaffective disorders
pp. 301-302(2)
Authors: Mosolov S.N.; Kostukova E.G.; Kouzavkova M.V.

Comparison of carbamazepine and beta-endorphin levels in manic states treatment
pp. 302-302(1)
Author: Procic V.A.

Experience with lithium/fluvoxamine combination: 36 cases
pp. 302-302(1)
Authors: Hopwood S.E.; Ashford J.J.; Prescott P.

A pilot study on the efficacy of sertraline and imipramine on anger attacks in atypical depression and dysthymia
pp. 302-303(2)
Authors: Fava M.; Nierenberg A.A.; Quitkin F.M.; Zisook S.; Rosenbaum J.F.

Sleep in depressed outpatients during treatment with fluvoxamine -- a home-based study
pp. 303-303(1)
Authors: Wilson S.J.; Bell C.; Coupland N.J.; Nutt D.J.

Fluvoxamine reduces somatic symptoms and is well tolerated in elderly depressed patients: results from the oldest reported population treated with a selective serotonin reuptake inhibitor
pp. 303-304(2)
Authors: Jaquenoud E.; Hochstrasser B.; Kat M.

Comparison of the safety and tolerance of fluvoxamine and sertraline in depressed outpatients
pp. 304-304(1)
Authors: Nemeroff C.B.; Ninan P.T.; Ballenger J.C.; Feighner J.; Greist J.H.; Patterson W.M.

Comparison of fluvoxamine and fluoxetine in major depression
pp. 304-304(1)
Authors: Rapaport M.; Coccaro E.; Sheline Y.; Holland P.; Perse T.; Fabre L.

Safety and tolerability of fluvoxamine in adolescent depression
pp. 304-305(2)
Authors: Alfonso M.; Ferrer R.; Such P.

Antidepressant actions on peripheral visual detection mechanisms in humans
pp. 305-305(1)
Authors: Weinstein A.; Wilson S.; Bailey J.; Nutt D.

A multicentre study of nefazodone and sertraline in depressed outpatients
pp. 305-306(2)
Authors: Burns T.; Kosky N.; Balasubramaniam K.; D'Souza J.; Andrews G.; Freeman C.; Buckingham S.; Hawkings E.; Mellors K.; Ascher A.

A multicentre comparison of nefazodone and paroxetine in depressed outpatients
pp. 306-306(1)
Authors: Baldwin D.; Hawley C.; Abed R.; Maragakis B.; White A.; Cox J.; Pover G.; Von Frenkell R.

Down regulation of 5-HT_2A receptors after chronic treatment with remeron
pp. 306-306(1)
Authors: Berendsen H.H.G.; Broekkamp C.L.E.; van Delft A.M.L.

Perspectives of use of calcium channels blockers for treatment of affective disorders (experimental data)
pp. 306-307(2)
Author: Kozlovsky V.L.

Effect of venlafaxine on rate and extent of improvement of depressive symptoms
pp. 307-307(1)
Authors: Hackett D.; Haudiquet V.; Danjou P.

An overview of the dose-response efficacy of venlafaxine with respect to treatment in different subclassifications of depressive illness
pp. 307-307(1)
Authors: Guichoux J.Y.; Hackett D.

Cardiac safety of venlafaxine
pp. 307-308(2)
Author: Danjou P.

A randomised, double-blind, comparison of the efficacy and safety of venlafaxine (75 to 150 mg/day) versus fluoxetine (20 mg/day) in depressed outpatients
pp. 308-308(1)
Authors: Salinas E.; Nicholas T.; Hackett D.

A randomized double-blind comparison of venlafaxine, imipramine and placebo in general practice patients with mild moderate depression
pp. 308-308(1)
Authors: Blanchard C.; Hackett D.; Danjou P.; Nicholas T.

Acute and continuation therapy with sertraline in major depression: a large-scale multicenter study
pp. 308-309(2)
Authors: Floris M.; De Nayer A.R.; Janssen F.; Van Houdenhove B.; Iancu H.; Boxus A.

A double-blind, multicentre study in primary care comparing paroxetine and clomipramine in patients with depression with associated anxiety
pp. 309-309(1)
Author: Hunter B.

A naturalistic prospective study of the efficacy and tolerability of fluoxetine in 244 unselected psychiatric outpatients. The importance of co-morbidity as a predictor of response
pp. 309-309(1)
Author: Blacker C.V.R.

The effects of trazodone on sleep: a clinical and EEG study in patients with major depression
pp. 309-310(2)
Authors: Arriaga F.; Paiva T.; Cavaglia F.; Pinheira G.

Trazodone and sleep disturbances induced by brofaromine
pp. 310-310(1)
Authors: Haffmans P.M.J.; Vos M.S.

Efficacy and safety of mirtazapine vs trazodone in hospitalised depressed patients
pp. 310-310(1)
Author: Van Moffaert M.

Evaluation of the potential pharmacokinetic interaction of venlafaxine and carbamazepine
pp. 310-311(2)
Authors: Wiklander B.; Danjou P.; Rolan P.; Tamin S.K.; Toon S.

The efficacy of tianeptine: an Indian study of one hundred and sixteen non-psychotic depressed patients
pp. 311-311(1)
Authors: Parikh R.M.; Sonwalla S.B.; Shah L.P.; Doshi B.S.

Paroxetine for treating depression in adolescents
pp. 311-311(1)
Authors: Rodriguez Ramos P.; Mardomingo Sans M.J.; San Sebastian Cabases J.; de Dios Vega J.L.; Sordo Sordo L.

Effect of clomipramine versus placebo on social adjustment in residual depression
pp. 311-312(2)
Authors: Rouillon F.; Waintraub L.; Markabi S.; Lancrenon S.

Fluoxetine in therapy of persons with PTSD
pp. 312-312(1)
Authors: Folnegovicacute Scaron malc V.; Folnegovicacute Z.; Kocijan D.; Kozaricacute D.; Makaricacute G.; Mimica N.

Neuroleptics in the therapy of delusional depression
pp. 312-312(1)
Authors: Cvjetkovicacute M.; Knezcaron evicacute A.; Nedicacute A.

The influence of doxepine treatment upon the changes of triglycerides and cholesterol level in anorexic patients
pp. 312-313(2)
Authors: Rajewski A.; Rajewska J.; Chlebowski T.

Fluvoxamin (Avoxin-KRKA) in the pharmacotherapy of mood disorders in elderly
pp. 313-313(1)
Authors: Mahnik M.; Hotujac L.; Vukelja D.; Mandicacute K.

Treatment of depressions in elderly GP-patients
pp. 313-313(1)
Author: Mikhailova N.M.

Clinical efficacy of paroxetine in elderly outpatients
pp. 313-314(2)
Authors: Zarattini F.; Testa L.

SSRIs in the treatment of depressed out patients aged 70 years and older
pp. 314-314(1)
Authors: Newhouse P.A.; Finkel S.I.; Richter E.M.

Double-blind comparison of sertraline and nortriptyline in late-life depression
pp. 314-314(1)
Authors: Finkel S.I.; Richter E.M.

Sertraline: an assessment of clinical benefit and cost in the UK
pp. 314-315(2)
Authors: Johnson N.J.; Lane R.

An open study of sertraline in fibromyalgia syndrome
pp. 315-315(1)
Authors: Syuertsen J.O.; Smedsrud T.; Lane R.M.

Combined therapy in treating poststroke depression
pp. 315-315(1)
Author: Marko M.

The non-responding major depressive patient -- the treatment-refractory major depressive patient
pp. 315-315(1)
Author: Drolsum B.A.

Analysis of the Hamilton depression rating scale factors -- fluoxetine vs. maprotiline
pp. 315-316(2)
Authors: Stankovicacute Z..; Zcaron ivkovicacute -Milovanovicacute D.; Bugarski-Kirola D.; Damjanovicacute A.

Effects of befloxatone on psychomotor performance and cognitive functions in elderly subjects
pp. 316-316(1)
Authors: Patat A.; Gandon J.M.; Le Coz F.; Durrieu G.; Cimarosti I.; Allain H.; Rosenzweig P.

Plasma concentration of MCPP after single oral dose administration of trazodone and MCPP in humans
pp. 316-316(1)
Authors: Lawlor B.A.; Radcliffe J.; Sunderland T.; Murphy D.L.

The neurochemical and behavioural effects of the isomers of mirtazapine in normal rats
pp. 316-317(2)
Authors: Norman T.R.; McGrath C.J.; Burrow G.D.

Effect D.N.Uznadze in paranoid schizophrenics: clinical and treatment perspectives
pp. 317-317(1)
Author: Pkhidenko S.V.

Soluble interleukin-6 receptors in schizophrenia: preliminary results
pp. 317-317(1)
Authors: Muuml ller N.; Empl M.; Putz A.; Schwarz M.; Ackenheil M.

Outcome predictors in first episode schizophrenia
pp. 317-318(2)
Authors: Amore M.; Magnani K.; D'Ambrosio S.; Mesa J..M.

Predictors of treatment compliance in long-term mentally ill
pp. 318-318(1)
Author: Middelboe T.

Are regional cerebral blood flow studies using single photon emission computed tomography (SPECT) reproducible in schizophrenia? Presentation of the protocol
pp. 318-318(1)
Authors: Walter M.; Leboul D.

Investigating dopamine receptor binding with PET and SPECT ligands in schizophrenia: clinical and methodological considerations
pp. 318-319(2)
Authors: Klimke A.; Boy C.; Muuml ller-Gauml rtner H.W.; Gaebel W.

Differential effects of S-ketamine and R-ketamine on psychopathology and brain energy metabolism measured by FDG-PET in humans
pp. 319-319(1)
Authors: Vollenweider F.X.; Leenders K.L.; Oslashye I.; Scharfetter C.; Angst J.

Eye fixations and recognition memory in schizophrenia
pp. 319-320(2)
Authors: Fleury E.; Buquet C.; Thomas P.; Goudemand M.; Hache J.C.; Charlier J.R.

Cerebral ventricles in chronic schizophrenia and ageing
pp. 320-320(1)
Authors: Medvedev A.V.; Valova O.A.; Savvateeva N.J.U.; Zharkova N.B.

Impaired performance on tests sensitive to fronto-subcortical dysfunction is related to both the positive and the negative dimensions of schizophrenia
pp. 320-320(1)
Authors: Mignone M.L.; D'Amato A.C.; Saviano P.; Mucci A.; Galderisi S.; Maj M.

Increased allergic reactivity of atopic type in major psychoses
pp. 320-321(2)
Authors: Dacedil bkowska M.; Rybakowski J.K.

Leucocyte arylsulphatase A activity in schizophrenia and depression
pp. 321-321(1)
Authors: Pelescaron A.M.; Jakovljevicacute M.; Kraccaron un I.; Ccaron accaron icacute A.; Miliccaron evicacute Z..

Clinical dimensions and neuroleptic dosage in newly admitted schizophrenic patients
pp. 321-321(1)
Authors: Troisi A.; Spalletta G.; De Angelis F.; Inzerilli G.; Ciani N.; Pasini A.

Functional etiology of schizophrenia as a new approach for specific treatment
pp. 321-321(1)
Authors: Trimarchi M.; Papeschi L.L.; Russo P.; Trimarchi C.P.; Guasco P.; Lugaresi E.; Nicolini M.

Fenfluramine challenge test in schizophrenia
pp. 322-322(1)
Authors: Mohr P.; Scaron raacute movaacute L.; Libiger J.

Vitamin B12 and folic acid deficiency in psychiatric in-patients
pp. 322-322(1)
Author: Sacute wiecedil cicki M.

New peculiarities of schizophrenic patients' reaction on psychopharmacotherapy
pp. 322-322(1)
Author: Malyarov S.A.

Anhedonia, displeasure capacity and blunted affect in schizophrenia
pp. 322-323(2)
Authors: Boyer P.; Loas G.; Legrand A.

Indices of serotonergic activity in suicidal patients with schizophrenic, affective and adjustment disorder
pp. 323-323(1)
Authors: Hawellek B.; Rao M.L.; Papassotiropulos A.; Deister A.; Laux G.; Mouml ller H.-J.

Studies on platelet serotonin system in hospitalized schizophrenics
pp. 323-323(1)
Authors: Folnegovicacute -Scaron malc V.; Jernej B.; Kozaricacute -Kovaccaron icacute D.; Makaricacute G.; Mimica N.; Banovicacute M.

Cannabis abuse and neurological abnormalities in schizophrenia: preliminary findings
pp. 323-324(2)
Authors: Bjouml rck R.V.; Nordin C.

Neuroleptic effectiveness prognosing in paranoid schizophrenia (clinical and neurophysiological aspects)
pp. 324-324(1)
Authors: Yurieva L.N.; Nosov S.G.

Is it true that schizophrenia is only mental disorder?
pp. 324-324(1)
Authors: Ilankovic N.; Ilankovic V.

Modelling attentional deficits in schizophrenia: hippocampal subfield lesions and performance of a 5-choice reaction time task in the rat
pp. 324-325(2)
Authors: Bratt A.M.; Stacey K.; Chase R.M.; Mittleman G.

MR imaging of selected brain structures and clinical improvement in schizophrenia
pp. 325-325(1)
Authors: Jarema M.; Choma M.; Poniatowska E.

Lack of myoglobinuria in acute psychosis with marked elevation in serum creatinine kinase
pp. 325-325(1)
Authors: Hermesh H.; Manor I.; Weizman R.; Munitz H.

Recurrence pattern of serum creatine phosphokinase levels in repeated acute psychoses
pp. 325-326(2)
Authors: Manor I.; Hermesh H.; Ratzoni G.; Munitz H.; Weizman A.

Treatment of schizophrenia with immunosuppressants
pp. 326-326(1)
Author: Shinitzky M.

Autoimmune response against autologous platelets in schizophrenia -- a basis for novel diagnostic and therapeutic approaches
pp. 326-326(1)
Authors: Deckmann M.; Shinitzky M.; Leykin I.; Cheng D.; Sirota P.; Avnon M.; Rafael C.

The Lidingo[uml ] investigation
pp. 326-326(1)
Authors: Flyckt L.; Taube A.; Edman G.; Petterson I.; Jedenius E.

Antipsychotic drugs differentially affect neurosteroid-induced modulation of the [³H]NE release evoked by NMDA in the rat hippocampus
pp. 326-326(1)
Authors: Monnet F.P.; Baulieu E.E.

D2-receptor occupancy related to neuroleptical doses, side effects and prolactin levels: a study with IBZM-SPECT
pp. 327-327(1)
Authors: Schlegel S.; Schloesser R.; Hiemke C.; Nickel O.; Bockisch A.; Hahn K.

Central effects of EMD 57445, a new sigma receptor ligand with a potential antipsychotic activity
pp. 327-327(1)
Authors: Maj J.; Skuza G.; Rogoacute z Z.

Induction of c-fos gene expression by the sigma receptor ligand and potential neuroleptic drug EMD 57445 in rat brain
pp. 327-328(2)
Authors: Dahmen N.; Fischer V.; Houml dl P.; Rujescu D.; Hiemke C.; Reuss S.

The effect of chlorpromazine on the induction of c-fos by electroconvulsive shock in the regions of rat brain
pp. 328-328(1)
Authors: Kim Y.S.; Ahn Y.M.; Kang U.G.; Park J.-B.

The effect of neuroleptics on the AP-1 DNA binding activity and the induction of fos and jun
pp. 328-328(1)
Authors: Ozaki T.; Katsumoto E.; Yokotani N.; Yamagami S.

Haloperidol and pimozide withdrawal: a comparison of behavioral and biochemical effects
pp. 328-329(2)
Authors: Michaluk J.; Romanacute ska I.; Vetulani J.; Antkiewicz-Michaluk L.

Selective activation by risperidone on serotonin but not dopamine metabolism in the rat prefrontal cortex
pp. 329-329(1)
Authors: Nomikos G.G.; Hertel P.; Marcus M.; Iurlo M.; Svensson T.H.

Effect of BIMG 80, a novel potential atypical antipsychotic, on dopamine levels measured by microdialys
pp. 329-329(1)
Authors: Volonteacute M.; Cerutti M.; Giraldo E.; Gil M.; Fodritto F.; Borsini F.

Pharmacological profile of BIMG 80, a novel potential atypical antipsychotic
pp. 329-329(1)
Authors: Brambilla A.; Cesana R.; Gil M.; Borsini F.

Antagonism of apomorphine-induced spontaneous eyeblinks in the rhesus monkey: possible differences among the antipsychotics haloperidol, risperidone, and remoxipride
pp. 330-330(1)
Authors: Kleven M.S.; Koek W.

In vitro and ex vivo patterns of occupation of 5-HT_2A and [alpha ]₁-adrenergic as compared to dopamine D₂ receptors by novel antipsychotics
pp. 330-330(1)
Authors: Audinot V.; Canton H.; Newman-Tancredi A.; Jacques V.; Verriegrave le L.; Millan M.J.

Comparative profiles of interaction of atypical antipsychotics at cloned human dopamine hD₂, hD₃ and hD₄ receptors: S 16924 shows a marked preference for hD₄ sites
pp. 330-331(2)
Authors: Audinot V.; Newman-Tancredi A.; Jacques V.; Chaput C.; Millan M.J.

Pharmacology of the potential antipsychotic EMD 57445 in animals and humans
pp. 331-331(1)
Authors: Bartoszyk G.D.; Bender H.M.; Heusener A.; Schnorr C.

Zotepine: preclinical tests predict antipsychotic efficacy and an atypical profile
pp. 331-332(2)
Authors: Needham P.L.; Skill M.J.; Heal D.J.

Binding of zotepine and other antipsychotics to cloned human dopamine receptors
pp. 332-332(1)
Authors: Needham P.L.; Atkinson J.; Heal D.J.

Seroquel^TM: new pre-clinical research data confirm atypical antipsychotic actions
pp. 332-332(1)
Author: Goldstein J.M.

The pre-clinical profile of the new antipsychotic ziprasidone
pp. 332-332(1)
Authors: O'Connor R.; Harrigan E.

d-Amphetamine-induced abnormal behavior in the rat antagonized by SCH 23390 or raclopride
pp. 332-333(2)
Authors: Salmi P.; Svensson T.H.; Ahlenius S.

Double-blind study of zotepine vs haloperidol in schizophrenia
pp. 333-333(1)
Authors: Petit M.; Raniwalla J.; Leutenegger E.; Tweed J.A.; Kelly F.

Sexual dysfunctions induced by typical and atypical antipsychotics
pp. 333-333(1)
Authors: Hummer M.; Kurz M.; Oberbauer H.; Kurzthaler I.; Schnegg G.; Fleischhacker W.W.

Haloperidol and reduced haloperidol discriminate sigma receptor subtypes in the neuronal response to N-methyl-D-aspartate in the rat hippocampus
pp. 333-334(2)
Authors: Monnet F.P.; Bowen W.D.; Baulieu E.E.

Disturbed thermoregulation in haloperidol-treated outpatients with chronic schizophrenia
pp. 334-334(1)
Authors: Hermesh H.; Manaim H.; Epstein Y.; Munitz H.; Birger M.

Antipsychotic treatment of different subtypes of schizophrenia
pp. 334-334(1)
Authors: Brazo P.; Dollfus S.; Zarifian E.; Petit M.

The use of antipsychotic medication in France and Great Britain: similarity or divergence?
pp. 334-335(2)
Authors: Dollfus S.; Van Os J.; Petit M.

Levosulpiride vs pimozide in negative symptoms of schizophrenia
pp. 335-335(1)
Authors: De Ronchi D.; Ruggeri M.; Balelli G.; Volterra V.

The use of anti-Parkinsonian drugs in hospitalized, psychotic patients on depot neuroleptics
pp. 335-335(1)
Authors: Drolsum B.A.; Johnsen T.

Sulpiride and risperidone vs. [ldquo ]classical neuroleptics[rdquo ] in schizophrenia: a follow-up study
pp. 335-336(2)
Authors: Kogeorgos J.; Kanellos P.; Michalakeas A.; Ioannidis J.

Clinical effects of I-sulpiride vs haloperidol in acutely relapsed chronic schizophrenics: therapeutic efficacy on [ldquo ]disorganization[rdquo ]?
pp. 336-336(1)
Authors: Guazzelli M.; Ciapparelli A.; Pietrini P.; Starnini S.; Sarteschi P.; Barracchia E.; Bertolino A.; Bertolino A.; Casacchia M.; Core L.; Fiori L.; Sodano A.J.; Pastore G.F.

Low doses of amisulpride in negative schizophrenia: A 99m-Tc HMPAO SPECT study
pp. 336-336(1)
Authors: Vaiva G.; Thomas P.; Dutoit D.; Fleury E.; Steinling M.; Goudemand M.

Pharmaco EEG effects of DU29894 -- a new dopamine antagonist and serotonin agonist
pp. 336-336(1)
Authors: Dietrich B.; de Koning P.

IBZM-SPECT and D2 dopamine receptor occupancy: different profiles with atypical neuroleptics
pp. 337-337(1)
Authors: Kuuml fferle B.; Bruuml cke T.; Tauscher J.; Schratzberger-Topitz A.; Asenbaum S.; Podreka I.; Kasper S.

NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia. A phase II clinical trial
pp. 337-337(1)
Authors: Karle J.; Gerlach J.; Clemmesen L.; Hansen L.; Andersen M.; Andersen J.; Fensbo C.; Lublin H.; Sloth-Nielsen M.; Skrumsager B.

Risperidone compared to novel and reference antipsychotic drugs for the in vivo occupancy of rat brain neurotransmitter receptors
pp. 337-337(1)
Authors: Schotte A.; Janssen P.F.M.; Bonaventure P.; Leysen J.E.

Patient requests and attitude towards neuroleptics
pp. 337-338(2)
Authors: Hoencamp E.; Knegtering H.; Kooy J.J.S.; van tier Moolen A.E.G.M.

Sleep evaluation in out-patients with oral neuroleptics
pp. 338-338(1)
Authors: Haffmans P.M.J.; Oolders H.; Hoencamp E.; Arends J.

The anticholinergic-neuroleptic association: a possible cause of confusional state in elderly people
pp. 338-338(1)
Authors: Principe L.; De Notaris E.; Pillo G.

Zuclopenthixol acetate in the treatment of psychotic anxiety
pp. 338-339(2)
Authors: Romain J.L.; Dermain P.; Gresleacute P.; Moisan P.; Nore D.; Pech G.

Psychosocial adjustment during neuroleptic continuation treatment: a study with the life skills profile in 200 DSM-IV chronic schizophrenic outpatients
pp. 339-339(1)
Authors: Zizolfi S.; Boreggio M.; Carfi' S.; Centorame F.; Cilli G.; Mastrolorenzo M.; Riva E.; Savini T.; Scagliotti A.

Clozapine induces improvement in very severe treatment-resistant schizophrenic patients: an open study on [ldquo ]depression[rdquo ] in schizophrenia
pp. 339-339(1)
Authors: Giordano L.; Schiazza G.; Tiberti T.; Nisticograve R.; Mattei P.; Stratta P.; Rossi A.

Clozapine treatment of young subjects affected with schizophrenia
pp. 339-340(2)
Author: Bruno V.

Therapy-resistant schizophrenia: a psychopharmacotherapeutic approach with an atypical antipsychotic drug (clozapine)
pp. 340-340(1)
Authors: Giannelli A.; Volonteacute M.V.

Adhesion to the treatment and relapses decrease with clozapine
pp. 340-340(1)
Author: Lupinski C.C.

Clozapine quantitative EEG profile: a multilead investigation
pp. 341-341(1)
Authors: Bucci P.; Romano G.; Tresca E.; Mucci A.; Galderisi S.; Maj M.

A two years follow-up of treatment-refractory schizophrenics treated with clozapine
pp. 341-341(1)
Authors: Vampini C.; Steinmayr M.; Bilone F.; Meruzzi G.; Robotti C.A.

Clinical efficacy of clozapine during the initial weeks of treatment. Effect on negative symptoms
pp. 341-341(1)
Authors: Llorca P.M.; Reine G.; Lanccedil on C.; Auquier P.; Bougerol T.

Effects of clozapine on plasma monoamine metabolites in treatment-refractory schizophrenic patients
pp. 341-342(2)
Authors: Min-Soo L.; Seung-Hyun K.

Clinical efficacy of clozapine in treatment-refractory schizophrenic patients
pp. 342-342(1)
Authors: Min-Soo L.; In-Kwa J.; Dong-Il K.

The role played by clozapine in the psycho-social rehabilitation program for chronic schizophrenic patients who present mostly negative symptoms
pp. 342-342(1)
Authors: Nicotra M.C.; Bilone F.; Robotti C.A.

Improvement of positive and negative symptoms during clozapine treatment in neuroleptic-resistant schizophrenics
pp. 342-342(1)
Authors: Jalenques I.; Albuisson E.

Prevention of relapse in schizophrenia with clozapine: an open mirror-image study of 53 outpatients treated up to 8 years
pp. 343-343(1)
Authors: Klimke A.; Klieser E.

Relapse prevention with clozapine in schizophrenic outpatients: plasma level, metabolism and compliance
pp. 343-343(1)
Authors: Klimke A.; Henning U.

Clozapine: the Indian experience with eighty-two patients of treatment resistant chronic schizophrenia
pp. 343-343(1)
Authors: Sonawalla S.; Parikh R.M.

Recurrence of transient near granulopenia but not true granulopenia during the initiation/early phase, of clozapine therapy
pp. 343-344(2)
Authors: Hermesh H.; Valevski A.; Dorfman-Etrog P.; Weisman A.; Munitz H.

Long term side effects in schizophrenia outpatients under neuroleptic treatment
pp. 344-344(1)
Authors: Chinchilla A.; Vega M.; Cebollada A.; Padiacute n J.J.; Diacute az M.; Guzmaacute n G.; Montes J.M.

Prospective four year follow-up study on clozapine treated patients: SPECT-HMPAO and clinical evaluation
pp. 344-344(1)
Authors: Medved V.; Hotujac L.; Petrovic R.; Dodig D.

Serum clozapine levels and clinical response -- results of therapeutic drug monitoring
pp. 344-344(1)
Authors: Grabe H.-J.; Rahn R.; Greb T.; Rao M.L.; Laux G.

Response to clonidine-haloperidol association in schizophrenic relapse predicts outcome of haloperidol-noradrenergic or serotoninergic antidepressant association
pp. 344-345(2)
Authors: Conte G.; Calzeroni A.; Ferrari R.; Guarneri L.; Pergami A.; Sacchetti E.

Mild neuroleptic malignant syndrome: problems of differential diagnosis
pp. 345-345(1)
Authors: Belelli G.; Pezzoli A.

Neuroleptic malignant syndrome following abrupt neuroleptic withdrawal
pp. 345-345(1)
Authors: Belelli G.; Pezzoli A.; Muraccini R.

Autoradiographic comparison of D₂- and D₃-dopamine receptor localization in the post mortem human brain using [¹²⁵I]epidepride and [³H]PD 128907
pp. 346-346(1)
Authors: Hall H.; Halldin C.; Suzuki M.; Dijkstra D.; Wikstrouml m H.; Wise L.D.; Pugsley T.A.; Hurd Y.; Farde L.; Pauli S.; Sedvall G.

Seroquel^TM and chlorpromazine in the treatment of hospitalised patients with acute exacerbation of subchronic and chronic schizophrenia. A multicentre, double-blind controlled study
pp. 346-346(1)
Authors: European SEROQUEL^TM Study Group.; Link C.G.G.; Smith A.; Ryan J.

Seroquel^TM treatment of hospitalised patients with acute exacerbation of chronic and subchronic sehizophrenia. A multicentre, placebo-controlled, double-blind study
pp. 346-346(1)
Authors: US SEROQUEL^TM Group.; Link C.G.G.; Arvanitis L.

Seroquel^TM treatment of hospitalised patients with acute exacerbation of subchronic or chronic schizophrenia. A multicentre, placebo-controlled, double-blind comparison of low and high dosage regimens
pp. 346-347(2)
Authors: Link C.G.G.; Arvanitis L.

Time course for dopamine and serotonin receptor occupancy in the brain of schizophrenic patients following dosing with 150 mg Seroquel^TM tid
pp. 347-347(1)
Authors: Gefvert O.; Lindstrom L.H.; Langstrom B.; Bergstrom M.; Lundberg T.; Yates R.A.; Larsson S.D.; Tuersley M.D.

Olanzapine versus haloperidol therapy for chronic schizophrenia: impact on deficit syndrome
pp. 347-347(1)
Authors: Revicki D.; Genduso L.

Effect of olanzapine on deficit syndrome symptoms in chronic schizophrenia
pp. 347-347(1)
Authors: Revicki D.; Genduso L.

Acute and long-term results of the North American double-blind olanzapine trial
pp. 347-348(2)
Authors: Tran P.V.; Beasley C.M.; Tollefson G.D.; Beuzen J.N.; Dellva M.A.; Sanger T.M.; Paul S.

Olanzapine in the treatment of dopaminomimetic psychosis
pp. 348-348(1)
Author: Wolters E.C.

Two open-label, long-term safety studies of sertindole
pp. 348-348(1)
Authors: Daniel D.; Staser J.; Schmitz P.; Sebree T.; Wallin B.

Efficacy and safety of sertindole in two double-blind, placebo-controlled trials of schizophrenic patients
pp. 348-349(2)
Authors: Targum S.; Zborowski J.; Henry M.; Schmitz P.; Sebree T.; Wallin B.

Ritanserin in neuroleptic induced akathisia: a double blind comparison with placebo
pp. 349-349(1)
Authors: De Col C.; Miller C.H.

A randomized double-bind trial of risperidone versus clozapine for treatment-resistant chronic schizophrenia
pp. 349-349(1)
Authors: Bondolfi G.; Baumann P.; Patris M.; May J.P.; Billeter U.; Dufour H.

Clinical efficacy of risperidone in idiopathic segmental dystonia
pp. 349-350(2)
Authors: Zuddas A.; Carta M.; Muglia P.; DeMontis N.; Cianchetti C.

Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia
pp. 350-350(1)
Authors: Jones B.; De Smedt G.; Lemmens P.

Risperidone in the treatment of first-episode patients with schizophreniform disorder: a double-blind multicenter study
pp. 350-350(1)
Authors: McCreadie R.; Livingston M.; Emsley R.A.; De Smedt G.; Lemmens P.

Risperidone in the treatment of schizophrenia: a double-blind comparison with haloperidol
pp. 350-350(1)
Authors: Murasaki M.; Miura S.

Efficacy of risperidone in treatment of paranoid symptoms in Alzheimer's disease (A.D.) and vascular dementia (V.D.)
pp. 351-351(1)
Authors: Wittgens W.; Klieser E.; Trenckmann U.; Beine K.

Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study
pp. 351-351(1)
Authors: Rossi A.; Mancini F.; Marola V.; Stratta P.; Casacchia M.; Gismondi R.; Pozzi F.

Risperidone in schizophrenia; clinical and biochemical results in 28 patients suffering from an acute psychotic episode
pp. 351-351(1)
Authors: Verhoeven W.M.A.; Hofma E.; van den Berg Y.W.M.M.; Kan C.

The efficacy and safety profile of a new antipsychotic, ziprasidone, in phase II studies
pp. 351-351(1)
Authors: Bradbury J.E.; Heym J.

Zuclopenthixol in the treatment of positive/negative schizophrenic symptoms
pp. 352-352(1)
Authors: Jarema M.; Szafranacute ski T.; Bialstrokek J.

Improvement in tardive dyskinesia, laterality of TD and cognition in schizophrenic patients changed from typical neuroleptics in risperidone
pp. 352-352(1)
Authors: Williams R.; Dickson R.; Caliguiri M.; Mahoney A.; Dalby J.T.; Yuen O.

Cost and benefits of clozapine at the CHG de Lagny
pp. 352-352(1)
Authors: Lochu A.; de Melo P.C.; Roche-Rabreau D.

Study of penicillin antiulcer and behavioural effects in rats (some new possibilities for its pharmacology)
pp. 353-353(1)
Author: Kalueff A.V.

Behavioral, monoaminergic, neuroendecrine and neuropeptidergic alterations in grown nonhuman primates exposed to unpredictable early rearing: relevance to human anxiety
pp. 353-353(1)
Authors: Coplan J.D.; Andrews M.W.; Rosenblum L.A.; Owens M.J.; Cooper T.; Gorman J.M.; Nemeroff C.B.

Alterations in nucleus accumbens dopamine receptors and in amphetamine-induced sensitization in prenatally stressed rats
pp. 354-354(1)
Authors: Henry C.; Gueacute gant G.; Cador M.; Le Moal M.; Demotes-Mainard J.

Influence of predictable and unpredictable chronic stress on phosphorylation of microtubule-associated proteins (MAPs) in rat brain
pp. 354-354(1)
Authors: Asakura M.; Sasuga Y.; Miyamoto S.; Imafuku J.; Osada K.; Aoba A.

Modulation of serotonin metabolism with 5-HT₁ agonistic compounds in self injurious behavior
pp. 354-355(2)
Authors: Verhoeven W.M.A.; Tuinier S.

Endogenous opioids and stereotyped behavior
pp. 355-355(1)
Authors: Tuinier S.; Verhoeven W.M.A.

CSF 5-HIAA and aggression; is there a relationship indeed?
pp. 355-355(1)
Authors: Tuinier S.; Verhoeven W.M.A.

Impulsive decision making in rats: the effects of drugs on a paced FCN8 schedule
pp. 355-356(2)
Author: Evenden J.L.

The effects of paroxetine and imipramine treatments on 35% CO₂ sensitivity in panic patients
pp. 356-356(1)
Authors: Bertani A.; Perna G.; Cocchi S.; Gabriele A.; Bellodi L.

Familial risk for panic disorder in panic patients: the effect of carbon dioxide sensitivity
pp. 356-356(1)
Authors: Perna G.; Bertani A.; Caldirola D.; Bellodi L.

The 35% CO₂ challenge test in social phobics: preliminary results
pp. 356-357(2)
Authors: Caldirola D.; Perna G.; Arancio C.; Cocchi S.; Bellodi L.

Efficiency of fluoxetine and dothiepine in treatment of panic disorder measured by 7% CO₂ challenge response
pp. 357-357(1)
Authors: Bocola V.; Del Trecco M.; Sollecito A.; Paladini C.; Trotta S.; Ferro F.M.

Stress: what kind of therapy?
pp. 357-358(2)
Author: Princet P.

What treatments do patients with panic disorder and agoraphobia get?
pp. 358-358(1)
Authors: Bandelow B.; Sievert K.; Hajak G.; Broocks A.; Ruuml ther E.

Validation of the new panic and agoraphobia scale in a clinical study
pp. 358-358(1)
Authors: Bandelow B.; Beinroth D..; Hajak G..; Ruuml ther E.

Panic disorder -- acceptance of the diagnostic entity and preferred treatment
pp. 358-358(1)
Authors: Bandelow B.; Rouml themeyer M.; Hajak G.; Ruuml ther E.

Predictors of time to relapse in a longitudinal study of panic disorder
pp. 358-359(2)
Authors: Pollack M.H.; Otto M.W.; Sabatino S.; McCardle E.; Rosenbaum J.F.

Heart rate and MHPG as predictors of nonresponse to drug therapy in panic disorder
pp. 359-359(1)
Authors: Slaap B.R.; van Vliet I.M.; Westenberg H.G.M.; den Boer J.A.

Diagnostic problems of somatoform disorders: a study comparing ICD-10 and DSM-III-R
pp. 359-359(1)
Authors: Sironi J.; Tacchini G.; Isaac M.; Janca A.

From DSM-III-R to DSM-IV: a study of the threshold problem of somatoform disorders
pp. 359-359(1)
Authors: Sironi J.; Isaac M.; Janca A.; Tacchini G.

A comparison of somatoform disorders in ICD-10 and DSM-IV: diagnostic consistency and internal validity
pp. 360-360(1)
Authors: Janca A.; Tacchini G.; Isaac M.; Sironi J.

Personality traits and platelet serotonergic measures
pp. 360-360(1)
Authors: Kozaricacute -Kovaccaron icacute D.; Jernej B.; Folnegovicacute -Scaron malc V.; Ljubin T.; Ccaron iccaron in-Scaron ain L.; Banovicacute M.; Nikscaron ic I.; Mihaljevicacute J.

Social phobia: a risk factor for eating disorders?
pp. 360-360(1)
Authors: Flament M.F.; Godart N.

A double blind study comparing a combined plant extract with placebo in the treatment of anxiety
pp. 361-361(1)
Authors: Bourin M.; Bougerol T.; Guitton B.; Broutin E.

Paroxetine, clomipramine and placebo in the treatment of panic disorder
pp. 361-361(1)
Authors: Judge R.; Dunbar G.

A fixed dose study of paroxetine (10 mg, 20 mg, 40 mg) and placebo in the treatment of panic disorder
pp. 361-361(1)
Authors: Dunbar G.; Steiner M.; Oakes R.; Gergel I.; Burnham D.; Wheadon D.E.

Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder
pp. 361-362(2)
Authors: Dunbar G.; Judge R.

The influence of metabolites on ferment status of white blood cells and students' psychological peculiarities
pp. 362-362(1)
Authors: Ternovsky L.N.; Ternovskaya V.A.; Ignateva S.N.

Correlation of ferment status, of lymphocytes, electrocardiography readings and corrective test in workers of cellulose-paper industry
pp. 362-362(1)
Authors: Ternovsky L.N.; Ternovskaya V.A.; Nartsissov R.P.

The professional deformation of the personality from the point of view of deontology
pp. 363-363(1)
Authors: Ternovsky L.N.; Ternovskaya V.A.

Immune cell responses as indicators of different 5-HT receptor sensitivity in high and low impulsives
pp. 363-363(1)
Authors: Hennig J.; Becker H.; Netter P.

Maintenance of remission in panic disorder: issues for cognitive-behavior therapy, pharmacotherapy, and their combination
pp. 363-364(2)
Authors: Otto M.W.; Pollack M.H.; Gould R.A.; Sabatino S.A.

Peripheral monoamines and CCK₄-induced panic attacks in healthy subjects
pp. 364-364(1)
Authors: Jerabek I.; Boulenger J.P.; Jolicoeur F.B.; Bradwejn J.; Drumheller A.; Lavalleacute e Y.J.

Short- and long-term discontinuation of alprazolam in patients with panic disorder with agoraphobia
pp. 364-364(1)
Authors: Corrigan H.; Jonas M.; Reimherr F.; Targum S.; Salzman C.

An evaluator blind, randomised, comparison of the safety and efficacy of alprazolam SR and clomipramine in panic disorder
pp. 364-364(1)
Authors: Holland R.L.; Musch B.C.

Treatment of school phobia in children with specific developmental disorders of scholastic skills
pp. 365-365(1)
Author: Krook I.V.

Baseline sexual functioning among unmedicated social phobics
pp. 365-365(1)
Authors: Koponen H.J.; Lepola U.; Leinonen E.

Platelet monoamine oxidase activity as predictor of recidivism into criminal activity
pp. 365-366(2)
Authors: Hallman J.; Lidberg L.; Oreland L.

Notes on combined treatment of bulimic disorder
pp. 366-366(1)
Authors: Fiorentini A.; Antonucci A.; Meldolesi G.N.

Methods of evaluation of agitation: a critical review
pp. 366-367(2)
Authors: Garre J.B.; Duverger P.; Feghoul H.; Lhuillier J.P.

A double-blind controlled study of PCR 7060 vs. buspirone in the treatment of generalised anxiety disorder
pp. 367-367(1)
Authors: Rouillon F.; Lejoyeux M.; Martineau C.

Two-year follow-up after treatment of panic disorder with agoraphobia with fluvoxamine, placebo, psychological panic management combined with exposure and of exposure in vivo alone
pp. 367-367(1)
Authors: van Balkom A.J.L.M.; de Beurs E.; van Dyck R.; Lange A.

Breathing irregularities in panic disorder patients
pp. 367-368(2)
Authors: Schwartz G.E.; Goetz R.R.; Gorman J.M.; Endicott J.; Klein D.F.

Opiate control of self-injury in mental retardation
pp. 368-368(1)
Author: Sandman C.A.

Carbon dioxide-induced panic in twins: preliminary results
pp. 368-368(1)
Authors: Arancio C.; Perna G.; Caldirola D.; Gabriele A.; Bellodi L.

The cortisol response to clomipramine in obsessive compulsive disorder: evidence to support a neuroendocrine serotonergic deficit?
pp. 368-369(2)
Authors: Martinez B.; Houml flich G.; Rao M.L.; Assion H.-J.; Eichert V.; Bagli M.; Papassotiropoulos A.; Kasper S.

Single photon emission computed tomography (HMPAO-SPECT) in obsessive compulsive disorder, after symptom provocation with m-chlorophenylpiperazine
pp. 369-369(1)
Authors: K. L.H.P.; de Leeuw A.S.; de Bruin W.I.; den Boer J.A.; Westenberg H.G.M.; Buijs J.; Anema P.; van Rijk P.P.

Pathological gambling and taurine in the cerebrospinal fluid
pp. 369-369(1)
Authors: Nordin C.; Bergh C.; Eklundh T.

Compulsivesive buying, depression and antidepressants
pp. 369-370(2)
Authors: Lejoyeux M.; Tassain V.; Adegrave s J.

Sequential administration of augmentation strategies in treatment-resistant obsessive compulsive disorder
pp. 370-370(1)
Authors: Blier P.; Bergeron R.; Heacute bert C.

Normal brain 5HT₂ receptors in obsessive-compulsive disorder demonstrated by positron emission tomography
pp. 370-370(1)
Authors: Biver F.; Goldman S.; Gribomont B.; Monclus M.; Danhaut P.; Mendlewicz J.; Lotstra F.

Pathogenetic mechanism of obsessive-compulsive disorder
pp. 370-371(2)
Authors: Kafka J.; Paacute lovaacute E.

Fronto-subcortical dysfunction and neuropsychological slowness in obsessive-compulsive patients
pp. 371-371(1)
Authors: Argenziano G.; Di Martino S.; Catapano F.; Mucci A.; Galderisi S.; Maj M.

Double-blind comparison of fluvoxamine and clomipramine in obsessive compulsive disorder in the United States
pp. 371-371(1)
Authors: Koran L.M.; McElroy S.L.; Davidson J.R.T.; Rasmussen S.A.; Hollander E.; Jenike M.A.

A Placebo controlled double blind study in obsessive compulsive disorder with fluvoxamine
pp. 371-372(2)
Author: Kudo Y.

Long-term treatment and prevention of relapse of obsessive compulsive disorder with paroxetine
pp. 372-372(1)
Authors: Dunbar G.; Steiner M.; Bushnell W.D.; Gergel I.; Wheadon D.E.

A double-blind, placebo-controlled trial of fluoxetine in patients with obsessive-compulsive disorder in Austria
pp. 372-372(1)
Authors: Meszaros K.; Dossenbach M.; Klech H.; Zitterl W.; Zitterl-Eglseer K.

Fluoxetine for treatment of obsessive compulsive disorders in adolescents. Preliminary data of an open study
pp. 372-373(2)
Authors: Vertucci P.; Bove R.M.; Scuccimarra G.

Long-term sertraline treatment of obsessive compulsive disorder: a 2 year study
pp. 373-373(1)
Authors: Rasmussen S.; Hackett E.; DuBoff E.; Greist J.; Halaris A.; Koran L.; Liebowitz M.; Lydiard R.B.; McElroy S.; Mendels J.; O'Connor K.

Anxiolytics and hypnotics: basic and clinical studies - Analysis of the anxiolytic-like effects of valproate on marble burying behaviour in mice
pp. 373-373(1)
Author: de Angelis L.

Anxiolytic activity of ondansetron in oxazepam tolerant rats
pp. 373-373(1)
Authors: Nowakowska E.; Chodera A.

CCK_B receptor antagonists in a novel animal model of panic-like anxiety
pp. 373-374(2)
Authors: Jenck F.; Moreau J.L.; Pommier M.; Martin J.R.

Is two-way shuttle-box avoidance performance modified in rats during withdrawal from chronic diazepam treatment?
pp. 374-374(1)
Authors: Zagbreve u U..; Palaogbreve lu O..; Ayhan I..; Ayvascedil ik B.; Soyguuml r H.

Would CCK-4 challenges be useful to predict anti-anxiety effects of non anti-panic drugs?
pp. 374-375(2)
Authors: Boulenger J.P.; Jerabek I.; Cocirc teacute G.; Lavalleacute e Y.J.; Jolicoeur F.B.

Effects of perinatal flumazenil on emotionality and shuttle box behavior in RLA/Verh rats
pp. 375-375(1)
Authors: Saacute nchez R.; Ferreacute P.; Fernaacute ndez-Teruel A.; Escorihuela R.M.; Reboreda M.C.; Tobentilde a A.

Alprazolam and handling-habituation antianxiety action in rats: effects of the type of handling exposure and drug doses
pp. 375-376(2)
Authors: Saacute nchez R.; Fernaacute ndez-Teruel A.; Escorihuela R.M.; Tobentilde a A.

Interrelationships between anxious personality and medical fears: an habituation study using exposure and benzodiazepine antagonists and agonists
pp. 376-376(1)
Authors: Saacute nchez R.; Torrubia R.; Caseras X.; Tobentilde a A.

Effects of flumazenil on recovery sleep and hormonal secretion after sleep deprivation in men
pp. 376-377(2)
Authors: Hemmeter U.; Seifritz E.; Trachsel L.; Lauer C.J.; Hatzinger M.; Emrich H.M.; Holsboer F.; Holsboer-Trachsler E.

Practical and theoretical significance of piricapiron anxiolytic
pp. 377-377(1)
Author: Dzub G.K.

Benzodiazepine receptor occupancy during lorazepam treatment in relation to plasma levels: a study with iomazenil-SPECT
pp. 377-377(1)
Authors: Schlegel S.; Hiemke C.; Schloesser R.; Nickel O.; Bockisch A.

Epidemiology of insomnia and use of psychotropic medications in a metropolis of a developing country
pp. 377-378(2)
Authors: Moussaoui D.; Kherrati H.; Touhami M.; Chergui M.; Essalaki F.; Salihy K.

Pharmacokinetic and pharmacodynamic interactions of zolpidem with fluoxetine in normal healthy volunteers
pp. 378-378(1)
Authors: Roth-Schechter B.; Piergies A.; Johnson M.; Allard S.

Effects of enalapril on sleep, plasma renin activity angiotensin II levels in healthy volunteers
pp. 378-378(1)
Authors: Kerkhofs M.; Antoine M.H.; Staroukine M.; Herchuelz A.

Comparative study of the efficacy of clonazepam and lithium in the treatment of acute mania
pp. 378-379(2)
Authors: Clark H.M.; Brook S.; Alwood C.W.

Sedation as a characteristic discriminating among antihistamines: clinical implications
pp. 379-379(1)
Authors: Soldatos C.R.; Dikeos D.G.

Protective properties of calcium antagonist nimodipine
pp. 379-379(1)
Author: Sukhotina I.A.

Impairment of NMDA-independent hippocampal synaptic plasticity in aging
pp. 379-380(2)
Authors: Diana G.; Loizzo A.; Domenici M.R.; de Carolis A.S.; Sagratella S.

Possible protective effects of co-dergocrine mesylate on antioxidant systems in aged rat brain
pp. 380-380(1)
Authors: Hariri N.I.; Souml zmen E.Y.; Kanit L.; Kutay F.

Oxytocin in aged rats: influence on memory and depression
pp. 380-380(1)
Authors: Arletti R.; Benelli A.; Poggioli R.; Cavazzuti E.; Bertolini A.